Navidea Biopharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference

JMP Securities Healthcare Conference 2014

DUBLIN, Ohio--()--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Michael Goldberg, M.D., Interim Chief Executive Officer, will participate at the 9th Annual JMP Securities Healthcare Conference June 24-25, 2014 at the Westin New York Grand Central in New York City, NY. Navidea’s presentation is on Tuesday, June 24, 2014 at 2:00 PM EDT.

Investors and the public are invited to the live webcast of Dr. Goldberg’s remarks at http://wsw.com/webcast/jmp24/navb/. Following the conference, the webcast will be archived for approximately 30 days.

About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is developing multiple precision diagnostic products and platforms, including NAV4694, NAV5001, Manocept™ and NAV1800 (RIGScan™), to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) Injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Contacts

Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Executive VP & CFO
or
Sharon Correia, 978-655-2686
Associate Director, Corporate Communications

Release Summary

Navidea to present at JMP Securities Healthcare Conference on June 24, 2014 at 2 p.m. EDT.

Sharing

Contacts

Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Executive VP & CFO
or
Sharon Correia, 978-655-2686
Associate Director, Corporate Communications